" class="no-js "lang="en-US"> Pison AI Technology Can Detect Early ALS Patients
Thursday, June 08, 2023

Landmark Study Finds Pison AI Technology Can Detect Neurological Disorder in ALS Patients

Pison, the pioneers behind AI-powered neural biosensors for health, wellness, and 3D touchless smart device control, today announced the results of recent clinical trial conducted by researchers at the Lewis Katz School of Medicine at Temple University’s MDA/ALS Center of Hope.

The trials concluded that Pison’s Neural Biosensor hardware and electroneurography (ENG) technology was able to distinguish patients with amyotrophic lateral sclerosis (ALS) from a healthy population and detect changes in surface electromyography (sEMG) in ALS patients which reflects motor neuron changes and is correlated with functional changes. These results demonstrate that Pison’s technology has the potential to become a digital biomarker to detect neurological diseases, monitor progression, and inform treatment. In addition, Pison’s ongoing efforts to embed their technology into wearable devices, such as smart watches, opens the door for continuous monitoring of patients and even pre-symptomatic populations.

The study, funded by The ALS Association and the National Science Foundation and led by Dr. Terry Heiman-Patterson, professor of neurology and director of the MDA/ALS Center of Hope at the Lewis Katz School of Medicine at Temple University, used Pison’s technology to classify electromyography activity and fasciculations in patients in the early stages of ALS. The study found that Pison’s technology could distinguish between patients diagnosed with ALS and a healthy population.

“New and better ways to diagnose and monitor people with ALS are urgently needed,” said Dr. Kuldip Dave, senior vice president of research at The ALS Association. “We are proud to have supported the initial testing of this promising new technology. We look forward to seeing the results of future studies to confirm and validate these findings with larger groups of participants.”

  1. Amarna Therapeutics Announces Appointment of Dr. Henk Streefkerk as New CEO Read more
  2. Aegis Life Awarded Grant to Develop DNA-encoded Antibodies Against Infectious Diseases Read more
  3. New “AI Doctor” Predicts Hospital Readmission and Other Health Outcomes Read more
  4. Axol Bioscience Collaborates with StrataStem to Deliver Stem Cell-Based ‘Clinical Trial in a Dish’ for Alzheimer’s Disease Read more
  5. MedTech Innovator Asia Pacific Names 24 Startups to Annual Accelerator Read more